Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/37605
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abd Rahman R. | en |
dc.contributor.author | DeKoninck P. | en |
dc.contributor.author | Murthi P. | en |
dc.contributor.author | Wallace E.M. | en |
dc.date.accessioned | 2021-05-14T12:48:04Z | en |
dc.date.available | 2021-05-14T12:48:04Z | en |
dc.date.copyright | 2018 | en |
dc.date.created | 20180205 | en |
dc.date.issued | 2018-02-05 | en |
dc.identifier.citation | Journal of Maternal-Fetal and Neonatal Medicine. 31 (4) (pp 525-529), 2018. Date of Publication: 16 Feb 2018. | en |
dc.identifier.issn | 1476-7058 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/37605 | en |
dc.description.abstract | In this review, we discuss the potential use of antimalarial drugs as an adjuvant therapy for preeclampsia, focusing on the mechanisms of action of this class of drugs in the context of preeclampsia. In particular, hydroxychloroquine has been shown to have various beneficial effects on patients with systemic lupus erythematosus. There are several pathways targeted by the antimalarial drugs that are similar to the pathophysiology of preeclampsia and hence offering opportunities to develop novel therapies to treat the disease. Given the safety profile of hydroxychloroquine in pregnancy, there is merit in exploring the efficacy of this drug as an adjuvant therapy in women with early onset preeclampsia.Copyright © 2017 Informa UK Limited, trading as Taylor & Francis Group. | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Taylor and Francis Ltd (E-mail: healthcare.enquiries@informa.com) | en |
dc.relation.ispartof | Journal of Maternal-Fetal and Neonatal Medicine | en |
dc.title | Treatment of preeclampsia with hydroxychloroquine: a review. | en |
dc.type | Review | en |
dc.identifier.affiliation | Obstetrics and Gynaecology (Monash Women's) | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/14767058.2017.1289511 | en |
dc.publisher.place | United Kingdom | en |
dc.identifier.orcid | Murthi, Padma; ORCID: http://orcid.org/0000-0003-2535-5134 Wallace, Euan M.; ORCID: http://orcid.org/0000-0002-4506-5233 | en |
dc.identifier.pubmedid | 28142291 [http://www.ncbi.nlm.nih.gov/pubmed/?term=28142291] | en |
dc.identifier.source | 620338254 | en |
dc.identifier.institution | (Abd Rahman) Department of Obstetrics and Gynecology, Faculty of Medicine, National University of Malaysia, Kuala Lumpur, Malaysia (DeKoninck, Murthi, Wallace) Department of Medicine, School of Clinical Sciences, Monash University, Monash Medical Centre, Clayton, VIC, Australia (Abd Rahman, Wallace) The Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia | en |
dc.description.address | E.M. Wallace, Department of Obstetrics and Gynecology, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, VIC 3168, Australia. E-mail: euan.wallace@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2018 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | antimalarial drugs mechanisms of action Preeclampsia | en |
dc.identifier.authoremail | Wallace E.M.; euan.wallace@monash.edu | en |
dc.description.grant | No: 1069364 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Obstetrics and Gynaecology (Monash Women's) | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.